BID Lab supports Brazilian HealthTech Timpel to improve the quality and efficiency of severe lung diseases treatments such as COVID-19 worldwide
Timpel's debt financing is part IDB Lab's Emergency Financing Line for Startups and Scaleups (LIFESS) and will benefit approximately 100 hospitals and more than 15,000 patients
As part of its program to support emerging entrepreneurs in the Latin America and Caribbean (LAC) to overcome the challenges of the COVID-19 pandemic, in August 2020, IDB Lab, together with its partner, FinHealth Fund, approved new debt financing to the Brazilian company Timpel to produce and sell high definition tomograms using Electrical Impedance Tomography (EIT) that provide live images of the breathing lung showing pulmonary performance in real time. A key tool for patients suffering of severe lung diseases.
The Brazilian startup, based in São Paulo, has developed a beside electrical impedance tomography (EIT) equipment – called ENLIGHT – that enables a portable, non-invasive and non-radioactive bedside lung monitoring, giving physicians and caregivers real time information on what is happening inside their patient’s lung, enabling them to individualize ventilation decisions, optimizing the strategy for treatment. It also reduces the need to move the patient to conduct CT in Radiology Units. This is especially important for COVID-19 patients who should be kept in isolation.
All these ENLIGHT features result in higher survival rates and less usage of Intensive Care Units (ICUs). Which makes ENLINGHT an unique, efficient and powerful tool for hospitals and patients fighting COVID-19.
About IDB Lab
IDB Lab is the IDB Group’s innovation laboratory to promote development through the private sector by identifying, supporting, testing and piloting new solutions to development challenges and seeking to create opportunities for poor and vulnerable populations in the LAC region. To fulfill its role, it engages and inspires the private sector and works with the public sector when needed. www.bidlab.org/en
Timpel is a fast growing medtech company that addresses the increasing need of precision medicine to improve chances of survival and to reduce the burden to the healthcare system of ventilatory support in Intensive Care Units, Operating Rooms and Ambulatory environments. Timpel’s solution is a bedside, radiation free and simple to use tomograph suitable for broad range of patients, from pre-term neonates with immature lungs to obese adult patients. Timpel is based in Sao Paulo and exports its solution to Europe, Middle East, Asia, North America and LATAM. http://www.timpelmedical.com/
FinHealth is a private equity and venture capital firm focused exclusively on venture and growth capital investments in healthcare companies of tomorrow. Finhealth’s mission is to invest in pre-commercial or commercial stage companies with highly differentiated products, technologies or services, achieving exceptional and consistent returns for their investors. FinHealth is primarily focused on Healthcare Services (specialized hospitals and clinics), Biopharmaceuticals for human health (including innovative drug development), Medical Devices/Diagnostics, Diagnostic Services and Digital Health. The Company builds long-term partnerships with entrepreneurs, investors, and industry collaborators creating trust, credibility, and value in business relationships.
Founded in 2009, FinHealth presently manages a portfolio of five leading innovative healthcare companies based in Brazil. BBI Financial I Fund managed by FinHealth holds over 25% of TIMPEL SA total capital. http://www.finhealth.com.br